Individuals who cannot attend the meeting in person can find webcast information on
ABOUT
Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and devices; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The company's fiscal 2014 revenue totaled $2.54 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
CONTACTS
Media
Communications Manager
314-654-8618
rhonda.sciarra@mallinckrodt.com
Senior Vice President, Communications and Public Affairs
314-654-3318
meredith.fischer@mallinckrodt.com
Investor Relations
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Vice President, Investor Relations
314-654-6650
john.moten@mallinckrodt.com
Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-bank-of-america-merrill-lynch-2015-health-care-conference-300076485.html
SOURCE